TROG Cancer Research
Members Login   CQMS Login

Closed Head & Neck trials

Trials closed to recruitment

TROG 14.03 (EORTC 1219) - the aim of this study is to determine whether the addition of nimorazole to the standard treatment (radiotherapy in combination with chemotherapy using cisplatin) shows activity against Locally Advanced Head and Neck HPV Negative Squamous Cell Cancers and is safe.

Primary sponsor: European Organisation for Research and Treatment of Cancer (EORTC)
Collaborating group: TROG; Danish Head and Neck Cancer Group (DAHANCA)

TROG 12.03 (EAT) - this study is evaluating the effectiveness of a dietitian delivered health behaviour intervention to reduce malnutrition in head and neck cancer patients undergoing radiotherapy.

Primary sponsor: University of Newcastle
Collaborating group: TROG

TROG 07.04 - the purpose of this study was to assess the safety and feasibility of combining radiotherapy and carboplatin (a chemotherapy drug) with a new drug called cetuximab in patients with locally advanced head and neck cancer.

Primary sponsor: TROG

TROG 07.03 (RadioHum) - this study has evaluated the benefits of humidification in patients receiving radiotherapy / chemoradiation for head and neck cancer.

Primary sponsor: TROG
Collaborating group: Fisher & Paykel Healthcare (FPH)

Completed trials

TROG 02.02 - Phase III Randomized Trial of Concomitant Radiation, Cisplatin, and Tirapazamine (SR259075) Versus Concomitant Radiation and Cisplatin in Patients With Advanced Head and Neck Cancer

TROG 01.01 - A Phase III Double-Blind, Randomized, Placebo-Controlled Study of Erythropoietin When Used as an Adjuvant to Radiation Therapy in Patients With Head & Neck Squamous Cell Carcinoma

TROG 98.02 - Randomised Phase II Study of Two Different Strategies for Chemoradiotherapy in Advanced Squamous Cell Carcinoma of the Head and Neck

TROG 91.01 - A Phase III Prospective Randomised Clinical Trial of Accelerated Radiotherapy (ART) for Stage III and IV Squamous Carcinoma of the Upper Aerodigestive Tract

We are thankful to our 14,500 patients who have participated in our research. Please continue the generous support.